WIDE Program: Worldwide Initiative to Develop Everolimus

This is an international website for The WIDE Clinical Development Program and is intended for Health Care Professionals outside the U.S. The information on the site is not country specific. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the US I am a US resident I am a patient outside of the US

Print This Page   E-mail-This Page
 
Novartis Oncology
Search :
 

Breast Cancer
   » Home » Breast Cancer
 

Everolimus (RAD001) in Breast Cancer—The BOLERO Program
     

What is the BOLERO clinical trial program?
Novartis has initiated the BOLERO (Breast cancer trials of OraL EveROlimus) clinical trial program to evaluate everolimus in locally advanced or metastatic breast cancer.

 BOLERO: Breast cancer trials of OraL EveROlimus
 
The BOLERO-4 and BOLERO-6 trials will soon be enrolling.
 
Disclaimer : These are investigational studies; there is no guarantee that everolimus will become commercially available for these indications
 
Disclaimer : This is an international web site for the The WIDE Program™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain information that is different from where you practice. Please contact your local Novartis Medical Scientific Liaison for the latest information specific to your country.
Home | Breast Cancer | Lymphoma MCL & DLBCL | Neuroendocrine Tumors - NETs
Renal Cell Carcinoma | Clinical Trial Finder | About Novartis | Tell a Colleague
Contact Us | Site Map | Terms of Use | Privacy Policy © Novartis AG
G-AFI-1036317